Skip to content

Study · Randomized controlled trial · n = 61 · 2002

5 results

The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study.

Yavuz MN, Yavuz AA, Aydin F, Can G, Kavgaci H

International journal of radiation oncology, biology, physics1 Sept 2002Cited by 46 (Europe PMC)

PMID12182992 (opens in a new tab)DOI10.1016/s0360-3016(02)02870-5 (opens in a new tab)PepBankPUB-12182992
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In radiation-induced diarrhea, complete resolution within 3 days occurred in 20 octreotide patients versus 4 diphenoxylate patients (p = 0.002).

    In plain wordsIn radiation-induced diarrhea, complete resolution within 3 days occurred in 20 octreotide patients versus 4 receiving diphenoxylate and atropine.

    Peptide
    Octreotide
    Outcome
    IncreaseComplete diarrhea resolution
    Study

    n = 61

    Comparator
    Diphenoxylate and atropine
    Analysis
    Primary
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 microg three times daily · subcutaneousAs given in this study (human).

    Measurements

    Complete diarrhea resolution
    2 patients
    octreotide arm, first day
    Complete diarrhea resolution
    11 patients
    octreotide arm, second day
    Complete diarrhea resolution
    7 patients
    octreotide arm, third day
    Complete diarrhea resolution within 3 days
    20 patients
    octreotide arm
    Complete diarrhea resolution within 3 days
    4 patients
    diphenoxylate and atropine arm, all within the second day

    Source sentences

    Summary
    Within 3 days, ARID completely resolved in 20 patients in the octreotide arm (2 within the first day, 11 within the second day, and 7 within the third day) vs. only 4 (all within the second day of therapy) in the diphenoxylate arm (p = 0.002).
    1 context sentence
    Summary · context
    Sixty-one patients with Grade 2 (four to six stools per day) or Grade 3 (> or = seven stools per day, National Cancer Institute Common Toxicity Criteria) diarrhea associated with pelvic radiotherapy were assigned randomly to receive octreotide s.c., 100 microg three times daily (n = 33) or diphenoxy…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In radiation-induced diarrhea, 6/33 octreotide patients versus 15/28 diphenoxylate patients discontinued pelvic radiotherapy (p = 0.003).

    In plain wordsIn radiation-induced diarrhea, fewer octreotide patients stopped pelvic radiotherapy than patients receiving diphenoxylate and atropine.

    Peptide
    Octreotide
    Outcome
    DecreaseRadiotherapy discontinuation
    Study

    n = 61

    Comparator
    Diphenoxylate and atropine
    Outcome group
    Treatment Interruption · Gastrointestinal
    Studied dose
    100 microg three times daily · subcutaneousAs given in this study (human).

    Measurements

    Patients discontinuing pelvic radiotherapy
    6 patients
    octreotide arm, of 33
    Patients discontinuing pelvic radiotherapy
    15 patients
    diphenoxylate and atropine arm, of 28

    Source sentences

    Summary
    On the diphenoxylate arm, 15/28 patients were required to discontinue pelvic radiotherapy; on the octreotide arm, 6/33 patients were required to discontinue pelvic radiotherapy for an average of 1.89 +/- 0.5 and 0.45 +/- 0.2 days, respectively (p = 0.003).
    1 context sentence
    Summary · context
    Sixty-one patients with Grade 2 (four to six stools per day) or Grade 3 (> or = seven stools per day, National Cancer Institute Common Toxicity Criteria) diarrhea associated with pelvic radiotherapy were assigned randomly to receive octreotide s.c., 100 microg three times daily (n = 33) or diphenoxy…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In radiation-induced diarrhea, average radiotherapy interruption was 0.45 +/- 0.2 days with octreotide versus 1.89 +/- 0.5 with diphenoxylate (p = 0.003).

    In plain wordsIn radiation-induced diarrhea, radiotherapy interruption averaged 0.45 days with octreotide versus 1.89 days with diphenoxylate and atropine.

    Peptide
    Octreotide
    Outcome
    DecreaseRadiotherapy interruption duration
    Study

    n = 61

    Comparator
    Diphenoxylate and atropine
    Outcome group
    Treatment Interruption · Gastrointestinal
    Studied dose
    100 microg three times daily · subcutaneousAs given in this study (human).

    Measurements

    Average radiotherapy interruption
    0.45 days
    octreotide arm
    Average radiotherapy interruption, +/- value
    0.2 days
    octreotide arm
    Average radiotherapy interruption
    1.89 days
    diphenoxylate and atropine arm
    Average radiotherapy interruption, +/- value
    0.5 days
    diphenoxylate and atropine arm

    Source sentences

    Summary
    On the diphenoxylate arm, 15/28 patients were required to discontinue pelvic radiotherapy; on the octreotide arm, 6/33 patients were required to discontinue pelvic radiotherapy for an average of 1.89 +/- 0.5 and 0.45 +/- 0.2 days, respectively (p = 0.003).
    1 context sentence
    Summary · context
    Sixty-one patients with Grade 2 (four to six stools per day) or Grade 3 (> or = seven stools per day, National Cancer Institute Common Toxicity Criteria) diarrhea associated with pelvic radiotherapy were assigned randomly to receive octreotide s.c., 100 microg three times daily (n = 33) or diphenoxy…
  4. 04HumanRandomized controlled trialSafety outcome

    In radiation-induced diarrhea, no side effects were observed with octreotide or diphenoxylate and atropine.

    In plain wordsIn radiation-induced diarrhea, no side effects occurred with octreotide or diphenoxylate and atropine.

    Peptide
    Octreotide
    Outcome
    No significant changeSide effects
    Study

    n = 61

    Comparator
    Diphenoxylate and atropine
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    100 microg three times daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    No side effects were observed in either arm.
    1 context sentence
    Summary · context
    Sixty-one patients with Grade 2 (four to six stools per day) or Grade 3 (> or = seven stools per day, National Cancer Institute Common Toxicity Criteria) diarrhea associated with pelvic radiotherapy were assigned randomly to receive octreotide s.c., 100 microg three times daily (n = 33) or diphenoxy…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In radiation-induced diarrhea, 1 octreotide patient versus three diphenoxylate patients required additional fluid, electrolyte, or antidiarrheal treatment.

    In plain wordsIn radiation-induced diarrhea, 1 octreotide patient versus three receiving diphenoxylate and atropine needed additional treatment.

    Peptide
    Octreotide
    Outcome
    DecreaseAdditional treatment requirement
    Study

    n = 61

    Comparator
    Diphenoxylate and atropine
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 microg three times daily · subcutaneousAs given in this study (human).

    Measurements

    Patients needing further treatment
    1 patients
    octreotide arm
    Patients needing further treatment
    3 patients
    diphenoxylate and atropine arm

    Source sentences

    Summary
    Three patients on the diphenoxylate arm and only 1 on the octreotide arm required further treatment for parenteral replenishment of fluids and electrolytes or other antidiarrheal treatments.
    1 context sentence
    Summary · context
    Sixty-one patients with Grade 2 (four to six stools per day) or Grade 3 (> or = seven stools per day, National Cancer Institute Common Toxicity Criteria) diarrhea associated with pelvic radiotherapy were assigned randomly to receive octreotide s.c., 100 microg three times daily (n = 33) or diphenoxy…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.